Alnylam Pharma is said to be a potential target for Novartis - Bloomberg

Nov. 18, 2021 7:19 AM ETAlnylam Pharmaceuticals, Inc. (ALNY)NVS, NVO, REGN, NTLABy: Joshua Fineman, SA News Editor10 Comments

Novartis Pharmaceuticals Canada Inc. head office building in Dorval, Quebec, Canada.

JHVEPhoto/iStock Editorial via Getty Images

  • Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis (NYSE:NVS) as investor push for the drugmaker to make an acquisition and use its cash. Alnylam rose 4.2% in premarket trading.
  • Alnylam, with a market cap of more

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.